Washington Post reports Eli Lilly moving against retatrutide copycats
Retatrutide remains investigational, yet copies of the triple agonist have circulated through gray-market and compounding channels.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 10 01:29 ETSource: The Washington Post
The wire
- 01The Washington Post's health briefing reports that Eli Lilly is taking action against sellers of copycat retatrutide.
- 02Retatrutide has not been approved, so any copied product reaching patients sits outside the regulated supply chain that pharmacists and telehealth operators rely on.
- 03Details of the specific legal or enforcement steps, and which sellers are targeted, were not laid out in the brief.
From the source
Read at washingtonpost.comHealth Brief: Eli Lilly takes on retatrutide copycats
